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Infectious complications are a major cause of morbidity and mortality in patients with primary or sec-
ondary immunodeficiency. Prevention of infectious diseases by vaccines is among the most effective
healthcare measures mainly for these subjects. However immunocompromised people vary in their
degree of immunosuppression and susceptibility to infection and, therefore, represent a heterogeneous
population with regard to immunization. To date there is no well- established evidence for use of vacci-
nes in immunodeficient patients, and indications are not clearly defined even in high-quality reviews and
in most of the guidelines prepared to provide recommendations for the active vaccination of immuno-
compromised hosts. The aim of this document is to issue recommendations based on published literature
and the collective experience of the Italian primary immunodeficiency centers, about how and when vac-
cines can be used in immunocompromised patients, in order to facilitate physician decisions and to
ensure the best immune protection with the lowest risk to the health of the patient.
 2018 Elsevier Ltd. All rights reserved.esare 11,
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Vaccinations are the most important tool to prevent infectious
diseases. Immunocompromised patients have an increased suscep-
tibility to infections that often affects the clinical outcome, thus
vaccination represents a critical issue in this population. The safety
and effectiveness of vaccines depends on the nature and degree of
immunosuppression. The response to vaccination is generally
reduced or completely absent in these patients, depending on
the type of immune disorders [1]. However vaccination studies
demonstrate, in many cases, an overall protective effect resulting
in reduced health-care costs and lower morbidity and mortality
rates. Currently, there are more than 300 primary immunological
disorders with different degrees of immune impairment and sus-
ceptibility to infection, which makes it difficult to draw universal
recommendations regarding immunization [2]. Therefore, vaccina-
tion schedule in people with immune deficiency requires a precise
assessment of risk-benefits to ensure the greatest protection, and
to prevent risks of adverse events in patients who are not deemed
eligible for vaccination. In the present review we report vaccine
schedule recommendations in patients with primary or secondary
immune disorders, based on the currently available evidence and
on the standardized experience and practice in the context of
the Italian Primary Immunodeficiency Network (IPINET) centers.
Of course their application must take into account the evolution
of knowledge in this field. Primary immunodeficiency were classi-
fied in 4 principal types, namely: B- cell defects and minor anti-
body deficiencies, T-lymphocyte deficiencies, immune disorders
characterized by selective susceptibility to infections and innate
immunity defects. A distinct section on ‘‘syndromic immunodefi-
ciency” has been included. Patients with secondary immune defi-
ciency (SID) represent a heterogeneous and continuously
increasing group of patients. SIDs are acquired and occurs in peo-
ple with HIV infection/AIDS, malignant neoplasms, stem cell or
solid organ transplantation, asplenia (functional, congenital ana-
tomic, or surgical asplenia); people receiving immunosuppressive
or antimetabolite drugs, and people with protein loss, chronic dis-
eases and inflammatory conditions (such as diabetes, kidney,
heart, liver or lung disease). In these patients short- and long-
term anti infectious prophylaxis mainly relies on vaccine and
antimicrobial treatments.2. Vaccination in antibody deficiencies (Table 1)
Primary antibody defects (PAD) represent more than 50% of all
primary immunodeficiencies and, according to the last classifica-
tion of the Union of Immunological Societies (IUIs) Expert Commit-
tee on Primary Immunodeficiency [2], can be divided into the
following groups, depending on their immunological features:
(a) severe reduction of all serum immunoglobulin isotypes with
profoundly decreased or absent B cells;
(b) severe reduction of at least two serum immunoglobulin iso-
types with normal or low B cells count;
(c) severe reduction of serum IgG and IgA with normal/elevated
IgM and normal B cells count;
(d) isotype or light chain deficiencies with generally normal B
cell counts;
(e) specific antibody deficiency with normal Ig concentrations
and normal B cell counts;
(f) Transient Hypogammaglobulinemia of Infancy with normal
B cell counts.
PAD feature an increased susceptibility to bacterial infections,
which mainly occur within the first years of age or after the thirddecade of life. Most infections are caused by encapsulated bacteria,
such as Streptoccoccus pneumoniae and Haemophilus influenzae [3].
However, both CNS infections by enteroviruses and gastrointesti-
nal infections by Giardia lamblia and Cryptosporidium may be
observed [4]. Furthermore, patients with PAD may develop
autoimmune diseases and/or neoplasia. Their natural history is
affected by the severity of hypogammaglobulinemia and the extent
of circulating B cell counts reduction. Therefore, some conditions
such as Selective IgA Deficiency (SIGAD) and Transient Hypogam-
maglobulinemia of Infancy (THI) are usually asymptomatic,
whereas others, such as X Linked Agammaglobulinemia and Com-
mon Variable Immunodeficiency (CVID) are characterized by sev-
ere and recurrent infections.
The management of antibody defects is tightly bound to its clin-
ical course, thus the prevention and monitoring of infectious epi-
sodes represent a key issue [5]. Immunoglobulin replacement
therapy, either administered intravenously or subcutaneously
and antibiotic therapy of acute infectious episodes, represent the
mainstays of treatment. Although antibiotic prophylaxis is used
in several clinical settings for an increased control of infectious epi-
sodes despite the high risk to induce antibiotic resistance.
Vaccination is a also used as diagnostic tool to assess specific
antibody response to protein and/or polysaccharide antigens. Cur-
rently growing evidence is available on the potential benefits of
this practice. However, caution is mandatory in some conditions
according to either severity or presence of associated diseases.
When contraindications to selected vaccines are not reported, tim-
ing and doses should follow national immunization recommenda-
tions [6,7]. Active immune response can be extremely
heterogeneous because vaccines can evoke either an adequate
response, as in healthy subjects, or an impaired/absent immune
response [5,8–10]. Additionally, the lapse of time between
immunoglobulins and vaccine administration is another important
factor that need to be considered [11]. Nowadays vaccines belong
to the two following categories:
– Inactivated vaccines;
– Live attenuated vaccines.
2.1. Inactivated vaccines
Inactivated vaccines consist of purified/synthesized antigens as
in vaccines against Tetanus, Diphtheria, Pertussis, Haemophilus
influenzae, Pneumococcus, Meningococcus (serotypes A, B, C,
W135, Y), Salmonella typhi, Hepatitis B virus, Papillomavirus or
inactivated microorganisms (Influenza virus). Generally, they are
considered safe and well tolerated as no relevant adverse
events have been reported in PID patients as compared to healthy
subjects [12].
As advised by the Advisory Committee on Immunization Prac-
tices (ACIP), in light of the accumulating data of the 23-valent
pneumococcal polysaccharide vaccine (PPSV23) related immune
hyporesponsiveness, the 13-valent pneumococcal conjugate
vaccine (PCV13) is recommended for protection of high-risk
individuals of all ages. However a PCV13/PPSV23 combined sched-
ule might be used to extend antibody responses to additional ser-
otypes [13,14].
To simplify the recommended timing in the age group 2–18
years, ACIP recently harmonized it as it follows: 8-week interval
for PCV13-PPSV23 sequence; 8-week interval for PPSV23-PCV13
sequence [14]. In CVID patients the antibody response to polysac-
charide antigens (meningococcal C and pneumococcal) may be
appropriated yet related to memory B cell count [10].
Papillomavirus vaccine is recommended in patients with pri-
mary immunodeficiency who have not been previously vaccinated
or have not completed the dose series, as reported by the Morbid-
Table 1
Vaccination in primary immunodeficiency disorders.
TDP IPV Hib HBV HPV Influenza Pneumococcus Meningococcus MMR
Varicella
Rotavirus BCG
S. typhi
Major antibody deficiencies (XLA, CVID) *Yes *Yes *Yes *Yes *Yes *Yes *Yes *Yes No No No
Minor antibody deficiencies (selective IgA
deficiency, isolated IgG subclass deficiency,
specific antibody deficiency)
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
SCID No No #Yes No No No #Yes #Yes No No No
CID #Yes #Yes Yes #Yes #Yes Yes Yes Yes §No §No No
MSMD #Yes #Yes #Yes #Yes #Yes #Yes #Yes #Yes No No No
Invasive bacterial infections #Yes #Yes Yes #Yes #Yes #Yes Yes Yes No No No
CMCD #Yes #Yes #Yes #Yes #Yes #Yes #Yes #Yes No No No
TLR deficiency #Yes #Yes #Yes #Yes #Yes #Yes #Yes #Yes No No No
IL12/IFN-gamma pathway deficiency #Yes #Yes #Yes #Yes #Yes #Yes #Yes #Yes No No No
Complement deficiency Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No data
available
Congenital defects of phagocytes (CGD,LAD,
MPO, Neutropenia)
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No
* May be administered when indicated: immune response may be impaired and is uncertain if depends only on humoral response.
 Not recommended: these vaccines are safe but probably ineffective.
# May be administered, the response to these vaccines is likely to be poor.
§ Generally contraindicated but they could be considered according to patient immune system function.
 Not recommended in LAD.
Footnotes: Pneumococcal Vaccines
PCV13 (1 dose) followed by PPV23 (1 dose at least 8 weeks after PCV13 and a booster 3–5 years later) in the case of anatomical/functional asplenia and congenital/acquired
immunodeficiency
PCV13 (1 dose) followed by PPV23 (1 dose at least 8 weeks after PCV13) in the case of complement deficiency, TLR 4 and properidin deficiency, hematopoietic stem cell
transplant, immunosuppression due to organ transplant, chemotherapy, high dose steroids, leukaemia, lymphoma, multiple myeloma and diffuse neoplasia.
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capsular polysaccharide Salmonella Typhi vaccine seems to be safe
in patients with PAD [16].
Inactivated vaccines consisting of purified antigens can be
administered to CVID and XLA patients even if it could not generate
a protective response. Conversely, patients with selective IgA defi-
ciency and IgG subclasses deficiency should receive vaccines
according to the immunization schedule for healthy subjects. Inac-
tivated poliovirus is the only polio vaccine recommended in
patients with antibody deficiency and their household contacts.
Of note, as reported in the ACIP Recommendations, some patients
may already be immune to poliovirus because they have been vac-
cinated before the diagnosis, but a protective immune response
may not be guaranteed in these subjects [17]. As reported by the
Infectious Diseases Society of America (IDSA) the inactivated influ-
enza vaccine (IIV) is recommended in patients with PAD aged >6
months [6]. Patients with hypogammaglobulinemia can mount a
CD4-mediated antibody response against influenza vaccine [18].
IIV vaccine, similarly to Pneumococcus vaccine, is also recom-
mended in patients receiving gammaglobulin replacement ther-
apy, as antibodies against influenza virus are not usually
included in immunoglobulin products, because of the viral antigen
variability. Furthermore, it could also stimulate an adequate pro-
tective response provided a residual immune function [5,6]. The
inactivated hepatitis A vaccine may be administered to patients
with antibody defects even if it could not generate a protective
response and additional doses may be required [19].
2.2. Live attenuated vaccines
As reported by Bonilla et al. [20] and Shearer et al. [21], live
attenuated virus vaccines are not recommended in XLA and CVID
patients because of their potential side effects. Actually, few data
are available on measles, chickenpox and rotavirus vaccines in
patients affected by PAD [21]. According to CDC, live attenuated
vaccines may be considered in these patients according to their
risk of exposure and immune status [11]. Rotavirus vaccine has
been added to the vaccination schedule. Two live attenuatedvaccines are currently available but new vaccines are being inves-
tigated. No data are available on the side effects of rotavirus vac-
cine in patients with PAD.
Therefore, this vaccine should not be given to patients with a
family history of primary immunodeficiency unless an immuno-
logical evaluation has ruled out a PAD [22].
In contrast, all available vaccines can be administered to
patients with IgA deficiency or IgG subclass deficiencies [21]. Yel-
low fever is still contraindicated in patients with PAD since no data
are available on the effects of this vaccine in this group of patients.
Indeed, patients with antibody deficiency may be at increased risk
of adverse events, such as visceral disease [23]. Live attenuated
poliovirus administration is per se not recommended in patients
with PAD and their relatives. Several studies have reported the
occurrence of CNS infection after poliovirus vaccine in XLA patients
[21] and, although less frequently, in CVID patients [24]. In partic-
ular, this vaccine could cause CNS invasive infection in patients
with undiagnosed PID or in those patients who have not started
gammaglobulin replacement [25]. Patients with PAD who are trav-
elling should be warned that immunoglobulin products contain
anti-poliovirus antibodies at various concentrations, suggesting
the exposure risk is still present in those areas where OPV vaccine
is used. Several studies have reported that in approximately 10% of
patients with PAD poliovirus excretion is still observed even sev-
eral months after vaccination [26]. Furthermore, this vaccine can-
not be used in selective IgA deficiency patients because some of
them can develop more severe primary immunodeficiency such
as CVID [5]. Live attenuated influenza vaccine (LAIV) is contraindi-
cated in XLA and CVID patients [27] as no data are available about
the infection or the virus spread from CVID patients vaccinated
with LAIV [28]. Furthermore, this vaccine is not recommended to
the household contacts for potential virus transmission. However,
in patients with minor antibody deficiencies, such as selective IgA
deficiency or IgG subclasses deficiencies, LAIV vaccine seems to be
safe, even if the immune response is impaired [21]. Live attenuated
bacteria vaccines include Bacillus Calmette-Guerin (BCG) and
Salmonella Typhi vaccines. Few studies are available about the
effects of these vaccines in patients with PAD, therefore they
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study on 50 XLA patients vaccinated with BCG demonstrates the
absence of systemic reactions and suggests its use in these patients
[21].
Salmonella attenuated Ty21a vaccine should not be used in
patients with PAD as reported in the CDC Morbility and Mortality
Weekly Report [16]. Although the Ty21a strain can be found in
the stools of vaccinated people, the transmission has not been
observed and blood cultures remain negative after vaccination
[16]. Moreover, in the mouse model the occurrence of a moderate
immune defect does not increase the susceptibility to Salmonella
Typhi infection after vaccination. Despite this evidence, the vaccine
is currently contraindicated [5].2.3. Vaccines and replacement therapy
Before a vaccine is administered, information on whether and
when gammaglobulin replacement therapy has been last per-
formed is required. Available products contain antibodies with a
wide range of immunological and anti-microbial effects such as
neutralization of bacterial toxins, opsonization for complement-
mediated lysis, opsonization for killing by phagocytes and cell-
mediated killing of pathogens induced by NK cells or phagocytes
[29]. Inactivated antigens, which include recombinant vaccines,
are generally not affected by circulating antibody, so they can be
administered before, after, or at the same time as the antibody.
Immunoglobulin therapy may interfere with immune responses
to measles, rubella and varicella live vaccines. The effect on mumps
vaccine is not known. Therefore, it is recommended to avoid these
vaccines for a period between 3 and 12 months after receiving
immunoglobulin, depending on the dose given [27]. Simultaneous
administration of antibody (in the form of immune globulin) and
vaccine is recommended for postexposure prophylaxis of certain
diseases, such as hepatitis B, rabies, and tetanus [19].3. Vaccination in major T-cell deficiencies and defects in
intrinsic immunity with susceptibility to specific organisms
(Table 1)
SCID is a congenital disorder characterized by the impaired gen-
eration of a diverse repertoire of mature T lymphocytes, which
leads to a severe T lymphopenia with a lack of a T- and B-
dependent specific-antibody response. All patients have few autol-
ogous T cells, while half the patients show a decreased number of B
and NK cells. Even if B cell counts may be normal or increased in
some patients with SCID, their maturation in SCID infants is incom-
plete and fail to produce specific antibodies. Thus, IgA and IgM con-
centrations are extremely low, while IgG concentrations are
related to the mother’s IgG levels at birth and decrease after 3
months. Other laboratory features of SCID patients include unde-
tectable T-cell receptor excision circles (TRECs), very poor mitogen
response and absence of the thymus. Patients with SCID display
profound immunodeficiency, which leads to severe susceptibility
to infections. Therefore, SCID diagnosis should be made early in life
to prevent patients exposure to infectious agents and perform
hematopoietic stem cell transplantation. No live viral or bacterial
vaccines should be given to SCID patients [21] who should other-
wise receive passive immunization with immunoglobulins. In fact,
disseminated vaccine- acquired varicella and vaccine acquired-
rubella have been reported in a 13 month-old female with an atyp-
ical SCID due to IL7R mutation [30]. Killed or inactivated vaccines
are safe because they cannot replicate. Nevertheless, their effec-
tiveness is very limited. Bacterial conjugate polysaccharide vacci-
nes, including pneumococcal, meningococcal and Haemophilus
influenzae type b vaccines, are recommended even in patients withcomplete T cells defect, but immune response to those vaccines is
likely to be poor. Oral Polio vaccine (OPV) should not be adminis-
tered to immunocompromised patients or to their household con-
tacts. In most countries, inactivated Poliovirus vaccine (IPV) has
replaced OPV vaccine. Recently in the United States a case of
vaccine- associated paralytic poliomyelitis has been described in
a child with SCID and a history of OPV vaccination in India [31].
Live-attenuatedM. bovis bacille Calmette-Guérin (BCG) is routinely
administered in most countries within the first month of life. How-
ever, only a small number of SCID patients receive diagnosis before
the age of 1 month, as the median age at diagnosis is 138.5 days
[32]. Marciano et al. reported BCG complications in 51% of SCID
patients vaccinated before SCID diagnosis, two-thirds dissemi-
nated and one-third localized, especially in those vaccinated
within the first month of life [33]. Thus, the absolute contraindica-
tion of BCG vaccine in SCID patients is not sufficient to prevent vac-
cine complications. This suggests that BCG vaccination should not
be performed in children with familial history of PID. Moreover, in
countries where newborn screening for SCID is available, BCG vac-
cination should be shortly postponed.
Oral rotavirus vaccine is also a live vaccine that is recom-
mended at two months of life in the United States and in several
European countries. Nine patients who received rotavirus vaccina-
tion before SCID diagnosis have been reported. They presented
with a severe gastroenteritis associated with protracted viral shed-
ding, which led to the diagnosis of SCID. Thus, as for other live vac-
cines, SCID is a contraindication for rotavirus vaccination [34].
However, a delay in rotavirus vaccination cannot be considered
because rotavirus vaccination must be administered early in life
to prevent the first yet most severe infection in children. The only
strategy to avoid rotavirus vaccination in SCID patients is early
diagnosis through newborn screening, if available.
Combined immunodeficiency (CID) is characterized by
impaired, but not completely absent, T- and B-cell immunity and
by less profound immunological abnormalities than SCID, such as
reduced in vitro T-cell function and thymus output. The diagnosis
of CID is often delayed because the clinical course is usually less
severe than SCID and newborn screening programs fail to identify
CID with normal TRECs levels at birth [35]. In patients with impair-
ment of T-cell functions, live viral vaccines are contraindicated, but
live measles, mumps, rubella and varicella vaccines could be con-
sidered in patients according to the immune system function.
Moreover, inactivated viral and bacterial vaccines are safe and vac-
cines against Streptococcus pneumoniae, Haemophilus influenzae
type b and Neisseria meningitides are recommended. However,
the response could be poor and a misdiagnosed immunodeficiency
could reveal itself as a vaccine response failure [36,37].
PIDs associated with alteration of Toll-like-receptor signaling
(TLR) are caused by distinct genetic defects that result in impair-
ment of cytokines production, cellular activation and, in some
cases, adaptive immune responses. Genetic alterations of UNC93B1,
TBK1, TRIF, TICAM1, TLR3, TRAF3 genes confer a peculiar and selec-
tive susceptibility to Herpes simplex encephalitis type 1 [27]. Men-
delian susceptibility to mycobacterial diseases (MSMD) is
characterized not only by inherited predisposition to infections
mainly caused by poorly virulent mycobacteria, but also by
Mycobacterium tuberculosis. Affected individuals are also predis-
posed to infections caused by Salmonella and other intracellular
bacteria (Listeria, Nocardia and Klebsiella), fungi (Candida, Histo-
plasma, Paracocidomyces), parasites (Leishmania, Toxoplasma) and
viruses (Cytomegalovirus, Human Herpes Virus 8 and Varicella Zoster
Virus) [38]. The genes causing MSMD (IFNGR1, IFNGR2, STAT1,
IRF8, GATA2, CYBB, IL12B, IL12RB1, ISG15 and NEMO) are involved
in the IL-12/IFN-c axis which are triggered by BCG [39,40]. After
BCG vaccine, patients with MSMD can develop localized (such as
lymphadenitis or osteomyelitis) or disseminated (fever, weight
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case of fatal disseminated BCG infection led to the identification
of the IFN-c receptor deficiency [41]. In 1998, inherited IL-12 defi-
ciency was identified in a patient with a history of BCG lym-
phadenitis and Salmonella enteritidis disseminated infection [42].
Disseminated osteomyelitis mimicking metastatic neuroblastoma
was found in a patient with heterozygous mutation in STAT1 [43].
As previously discussed, the absolute contraindication of BCG
vaccine in immunocompromised patients is not enough to prevent
complications. Thus, while it is necessary to develop a safer vac-
cine, it is important to identify high-risk patients, such as patients
with a family history of consanguinity, immunodeficiency or vac-
cine complications.
Predisposition to invasive bacterial infections, mostly caused by
S. pneumoniae, S. aureus, and P. aeruginosa is associated with inher-
ited mutations in IRAK4, NEMO and MYD88 [44]. Recommenda-
tions to manage predisposition to invasive bacterial infections
include antibiotic prophylaxis, IVIG replacement therapy and vac-
cination with both 13-valent pneumococcal conjugate vaccine
(PCV-13) and 23-valent pneumococcal polysaccharide vaccine
(PPSV23), Haemophilus type b conjugate vaccine and Neisseria
meningitides conjugate (Men A,C,W,Y) or subcapsular protein
(MenB) vaccine. Patients require repeated vaccination and recur-
rent determination of the antibody response. However, a fatal
pneumococcal meningitis despite PCV-13 vaccination 6 weeks
before and a satisfactory IgG response to vaccine antigens in a 7
year-old girl with IRAK-4 deficiency [45]. Thus, the vaccine strat-
egy is not sufficient to prevent IPD in high-risk patients because
the antibody response against vaccine antigens could not ensure
the protection against natural exposure to S. pneumoniae. Chronic
mucocutaneous candidiasis disease (CMCD) is characterized by
impaired IL-17 immunity, which leads to an increased susceptibil-
ity to recurrent and persistent infections of skin, nails and mucosae
caused by Candida species [46]. The majority of CMCD cases are due
to heterozygous STAT1 gain-of-function mutations (GOF). How-
ever, other genes associated with CMCD have been identified,
namely: STAT3, CARD9, AIRE, IL-17RA, IL17RC, IL17F, CLEC7A and
TRAF3IP2. CMCD is not only associated with localized fungal infec-
tions, but also with bacterial and viral infections, invasive fungal
infection, autoimmunity and cancer. In a cohort of 274 patients
with STAT1 GOF mutations, Toubiana et. all reported localized
and disseminated disease caused by BCG vaccine and severe dis-
ease due to live viral vaccine (smallpox and measles) [47,48]. Inac-
tivated vaccines can generally be administered, while live
attenuated pathogens are contraindicated.4. Vaccination in innate immunity deficiency (Table 1)
4.1. Phagocytic defects
Patients affected by inherited disorders of phagocytes show an
increased susceptibility to bacterial infections, especially to
Staphilococcus aureus, Serratia marcescens, Nocardia spp, Burkholde-
ria cepacia and fungi as Candida and Aspergillus. The prototype of
these disorders is the Chronic Granulomatous Disease (CGD) [49].
Although preventive strategies for most infections that occur in
this disorder are not available, active immunization policy is highly
recommended. Even in the absence of controlled trials, vaccines
with inactivated germs are considered useful, safe and well toler-
ated [6]. Conversely, as for the administration of vaccines with live
viruses, previous evaluation by an Immunologist should be sought.
In particular, while patients affected by CGD or congenital neu-
tropenia are capable to respond properly to antigenic stimulation
of live viruses vaccines, in a few cases affected by Leukocyte Adhe-
sion Deficiency (LAD) or Chediak-Higashi syndrome (CHs), which ischaracterized by a failure in releasing the cytolytic granules, severe
side effects have been reported as a consequence of the impair-
ment of cell mediated and cytolytic activity [50,51]. Furthermore,
it has been reported that CGD patients display significantly lower
antibody titers against measles and not fully characterized abnor-
malities of the B-cell compartment, hence a suspect defect in long-
term maintenance of the memory response [52]. An increased risk
of bacterial complication of viral infections (such as staphylococcus
infections on varicella lesions) should be considered in patients
with neutropenia, so that, with the exception of LAD or CHs, viral
vaccines are recommended in those patients.
As for attenuated live bacterial vaccines, an increased risk to
develop a disseminated form of Mycobacteriosis following BCG
vaccination has been reported even a long time after the vaccina-
tion [53,54]. Multiple BCG reactivations can also occur [55]. Several
studies show that 62–75% of the CGD patients with mycobacterial
complications had BCG-related disease [56]. Conversely, the risk of
disease caused by environmental mycobacteria seems very low.
Therefore, BCG vaccination is contraindicated in patients with a
diagnosis of CGD and needs to be delayed in their newborn sib-
lings. Despite the lack of data in the literature, live Salmonella typhi
vaccines should be avoided, due to the high occurrence of such
infections in CGD patients [57]. While inactivated Salmonella thyphi
vaccines can be used. Aspergillus fumigatus is a common cause of
infection in CGD patients, but unfortunately no specific vaccine is
currently available for this pathogen. However, in a mouse model
of CGD a long-lasting antifungal protection leading to the disease
control was successfully achieved through the vaccination with
purified fungal antigens that can activate CD4+ T cells, suggesting
a new potential preventive approach for this condition [58].
4.2. Complement deficiency
Complement deficiency (CD) is a group of rare primary immun-
odeficiencies characterized by a high susceptibility to invasive bac-
terial infections, mainly caused by encapsulated pathogens as
Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus
influenza; immune dysregulation and autoimmunity [6,59]. Differ-
ent degrees of severity and type of infections have been reported
within the three major activation pathways, namely the classical
pathway (CP), the alternative pathway (AP) and the lectin pathway
(LP). Since CP components are essential for the response against
encapsulated bacteria, the spectrum of infections observed in these
patients is similar to that observed in patients affected with other
primary B-cell disorders. Deficiency in the LP, also known as
Mannan-Binding Lectin (MBL) pathway, is usually asymptomatic
or responsible for airways or skin recurrent bacterial infections.
Chronic cryptosporidial diarrhea, meningococcal meningitis, recur-
rent herpes simplex infections have also been reported. Patients
diagnosed with the extremely rare deficiency of ficolins suffer from
multiple and precocious lower respiratory tract infections and
recurrent warts. Deficiencies in either factors involved in the AP
(i.e. properdin, factor B and D) or proteins involved in the terminal
sequence (i.e. C5, C6, C7, C8 and C9) are mainly associated with a
significant risk to develop meningococcal disease (7000- to
10,000-fold higher risk). In particular, it has been estimated that
nearly 50% of subjects lacking a terminal complement component
had an invasive meningococcal disease in their life with a high risk
of relapse within one month after the first infection, suggesting
that the infection itself does not provide full protection. Thus far,
no significant adverse events related to vaccines have been
reported in CD patients. The occurrence of post-vaccine
immunocomplex-mediated glomerulonephritis has been described
in a patients with C2 deficiency who had received the first dose of
the combined vaccine with purified antigens [60]; but, the
presence of specific antigens was not detected in glomerular
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lonephritis has been described in C2 deficient patients as well,
without correlation with previous vaccination.
Concerning the effectiveness of vaccination, few studies are
available in patients with CD. The serum bactericidal and
opsono-phagocytosis activity of patients with CD, who had
received an anti-meningococcal tetravalent polysaccharid vaccine
(MPSV), were similar or only slightly lower than those of healthy
subjects. However, a significantly increased risk of meningococcal
disease persisted in the years following the vaccine administration,
especially in the cohort of children who had developed a lower
antibody titer [61,62]. A subsequent study, performed on 22 C2-
deficient patients, who had received a tetravalent polysaccharide
vaccine [63] reported a normal antibody response against the ser-
ogroups C, Y and W, but lower against the serogroup A. Based on
these observations, all vaccines, including viral vaccines, can be
considered safe and sufficiently immunogenic. In particular, conju-
gate vaccines (pneumococcal, anti-haemophilus influentiae and
anti-meningococcus) are strongly recommended in patients suffer-
ing from both early component and late component deficiency.
Additional immunization against these pathogens is indicated: a
booster dose of tetravalent conjugate meningococcal vaccine every
3 years for 2 month- to 6 year- old patients, or every 5 years for
patients older than 6 years of age [6]. Furthermore pneumococcal
conjugate vaccine (PCV13) should be followed by pneumococcal
polysaccharide 23 vaccine (PPV23) 8 weeks later, to retain protec-
tion levels of antibodies [1,64,65].5. Vaccination in syndromic immnodeficiencies (Table 2)
5.1. Hyper IgE-syndrome
Hyper-IgE syndrome (HIES) is characterized by eczema, mainly
at birth or within the first years of life, severe cutaneous infections
and skin abscesses, pyogenic pneumonias with tendency to pneu-
matocele and mucocutaneous candidiasis. Lymphadenitis, sinusi-
tis, otitis, arthritis, osteomyelitis and sepsis are common as well.
Most cases are sporadic, but autosomal dominant and recessive
forms are mainly due to mutations of STAT3 gene (AD-HIES) and
of dedicator of cytokinesis 8 gene (DOCK8) or PGM3 (AR-HIES)
respectively. Few autosomal recessive cases caused by Tyk2 muta-
tions have been identified as well [66–68]. STAT3 signaling isTable 2
Vaccination in syndromic immunodeficiency.
TDP IPV Hib HBV HPV Influenza Pneumo
Complete Di George
syndrome
No No *Yes No No *Yes *Yes
Partial Di George syndrome Yes Yes Yes Yes Yes Yes Yes
Ataxia-Telangiectasia Yes Yes Yes Yes Yes Yes Yes
Wiskott-Aldrich syndrome Yes Yes Yes Yes Yes Yes Yes
Hyper IgE syndrome Yes Yes Yes Yes Yes Yes Yes
IPEX syndrome Yes Yes Yes Yes Yes Yes Yes
APECED syndrome Yes Yes Yes Yes Yes Yes Yes
 Not recommended: these vaccines are safe but probably ineffective.
* May be administered, the response to these vaccines is likely to be poor.
& Can be administer only if T CD4+ lymphocytes> = 500 cells/microliter, T CD8 + lym
Center for Disease Control and Prevention recommends higher CD4+ levels if children ar
1500 cells/microliter under one year of life (Red Book, 29th Edition 2012, Report of the
Footnotes: Pneumococcal Vaccines
PCV13 (1 dose) followed by PPV23 (1 dose at least 8 weeks after PCV13 and a booster 3–
immunodeficiency
PCV13 (1 dose) followed by PPV23 (1 dose at least 8 weeks after PCV13) in the case of
transplant, immunosuppression due to organ transplant, chemotherapy, high dose sterorequired for the differentiation of naive T cells into Th17 lympho-
cytes that defend the host against extracellular pathogens and
fungi which explains the high susceptibility of HIES STAT3 patients
to these pathogens. Conversely, DOCK8 protein is involved at mul-
tiple stages in T cell development. Viral infections, mainly due to
Herpes simplex are frequently observed in these patients. Common
pathogens are Staphylococcus aureus, Haemophilus influenzae, Strep-
tococcus pyogenes group A, Pseudomonas aeruginosa, Escherichia coli.
Chronic candidiasis of mouth and nails is frequent, together with
invasive infections caused by Candida, Aspergillus, Criptococcus.
Some cases of Pneumocystis jiroveci pneumonia and nocardiosis
have also been described. In HIES patients all killed, inactivated
and recombinant vaccines are recommended. Many authors
demonstrate a variable capacity to produce protective antibody
response in these patients [69,70]. In particular, the administration
of two doses of conjugate vaccines (13-valent pneumococcal and
tetravalent anti- meningococcal Men A-C-W-Y vaccines) at 12-
month interval may be useful. Live attenuated viral vaccines can
be used without risks in AD-HIES patients. Conversely, live vacci-
nes should not be administered in HIES patients with DOCK8 or
PGM3 mutations with signs of T immune defects, as evaluated by
CD4+ T cell counts 500 cells/ll, CD8+ T cells 200 cells/ll and
normal T cells response to mitogen. Conversely, live attenuated
bacterial vaccines (BCG and Salmonella typhi vaccines) are con-
traindicated because of the common association with a functional
defect of anti- bacterial response.5.2. Wiskott-Aldrich syndrome
Wiskott-Aldrich syndrome (WAS) is a X-linked recessive disor-
der, characterized by thrombocytopenia with small platelets,
eczema, recurrent infections, increased risk of autoimmunity and
malignancy. It is caused by mutations in the WAS protein (WASP)
gene. Patients with WAS show a progressive immune impairment
over time, characterized by lymphopenia, hypogammaglobuline-
mia and reduction of antibody response in particular against
polysaccharidic antigens. Increased risk of encapsulated bacterial
but also viral and fungal infections has been described. Among
viruses, Herpes simplex type 1 and 2 are frequent and associated
with recurrent yet disseminated infections. Poxvirus and warts,
usually non responsive to common treatments, are described. Can-
dida and Pneumocystis jiroveci infections are frequent, too.coccus Meningococcus MMR
Varicella
Rotavirus BCG
S. typhi
*Yes No No No
Yes &Yes &Yes No
Yes &Yes No data
available
No
Yes No No No
Yes &Yes &Yes No
Yes No data
available
No data
available
No data
available
Yes No data
available
No data
available
No data
available
phocytes > = 200 cells/microliter and T lymphocytes mitogen response is normal.
e under 6 years: al least 1000 CD4+ cells/microliter between 1 and 6 years, at least
Committee on Infectious Diseases).
5 years later) in the case of anatomical/functional asplenia and congenital/acquired
complement deficiency, TLR 4 and properidin deficiency, hematopoietic stem cell
ids, leukaemia, lymphoma, multiple myeloma and diffuse neoplasia.
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mended, using both the unconjugated and conjugated forms as
appropriate. In particular patients aged 2–5 years should receive 1
dose of 13-valent pneumococcal conjugate vaccine (PCV13) if they
have received 3 doses of PCV (either 7-valent PCV [PCV7] or
PCV13) before age 24 months and 2 doses of PCV13 (8 weeks apart)
if they have received an incomplete schedule of 2 doses of PCV7
(PCV7 or PCV13) before age 24 months [6]. Live attenuated viral
and bacterial vaccines should not be administered, as a defective
number or function of T lymphocytes is common in these patients
[71].5.3. Ataxia-telangiectasia
Ataxia-telangiectasia is an autosomal recessive disorder caused
by mutations of ATM gene located on chromosome 11 that is
involved in DNA repair mechanisms. The defect induces a high fra-
gility of DNA, which leads to frequent translocations, inversions
and breakages of chromosomes. The first manifestation is the
appearance of progressive cerebellar ataxia over the first years of
life; mucocutaneous and ocular telangiectasia generally appears
afterwards, especially on the face and on the folds of knees and
elbows. These patients show increased susceptibility to respiratory
infections over time, with high risk of bronchiectasis or chronic
obstructive pulmonary disease. The increased susceptibility to
infections can also be due to ‘‘mechanical” causes (e.g. ab ingestis
pneumonia). Encapsulated germs, especially Haemophilus influen-
zae, Streptococcus pneumoniae and Pseudomonas aeruginosa, are
responsible for recurrent bacterial infections. Gastrointestinal
infections/infestations are frequent too. Immunological impair-
ment is the consequence of errors in VDJ recombination of T cell
receptor (TCR) and/or B cell receptor (BCR). In the case of a severe
reduction of CD4+ T cells, prophylaxis with cotrimoxazole against
Pneumocystis jiroveci is mandatory. Patients can safely receive
killed, inactivated and recombinant vaccines. Despite the reduced
specific antibody production against polysaccharides, conjugated
vaccines against Streptococcus pneumoniae, Haemophilus influenzae
and Neisseria meningitidis are effective and thus recommended.
Live attenuated viral vaccines can be administered only when
CD4+ T cells are 500 cells/ll, CD8+ T cells are 200 cells/ll and
T cells response to mitogen is normal [72,73].5.4. Di George syndrome
Di George syndrome, also termed as chromosome 22q11 dele-
tion syndrome or CATCH syndrome (Cardiac anomalies, Abnormal
facies, Thymic hypoplasia, Cleft palate, Hypocalcemia) is due to an
embryogenetic disorder from the third and fourth branchial
pouches. Di George syndrome may be sporadic or have an autoso-
mal dominant inheritance. Most cases display a ‘‘partial” DiGeorge
syndrome with residual thymus, milder T lymphocyte abnormali-
ties and lymphopenia. Humoral response is generally normal. Only
1% of patients are affected by the ‘‘complete” form with absence of
thymus. As this sign is typical of Severe Combined Immunodefi-
ciency (SCID) children, these PIDs share the same recommenda-
tions. All live attenuated viral and bacterial vaccines are
contraindicated because of the potential risk of vaccine-related dis-
eases. Conversely, vaccines against capsulated germs and inacti-
vated influenza vaccine are recommended [19].
As to the ‘‘partial” syndrome, the same recommendations
observed in partial defects of T lymphocytes are to be followed.
Vaccines against Streptococcus pneumoniae, Haemophilus influenzae
and Neisseria meningitidis and influenza are recommended. Live
attenuated viral vaccines can be administered if CD4+ T cells are500 cells/ll, CD8+ T cells are 200 cells/ll and T cell response
to mitogen is normal. If these criteria are not satisfied, delaying
the vaccination with immunological monitoring is advised. The
Center for Disease Control and Prevention recommends even
higher CD4+ levels in children below the age of 6 years, namely:
CD4+ 1000 cells/ll between 1 and 6 years and 1500 cells/ll
under one year of life [74].
5.5. IPEX syndrome (Immune dysregulation, polyendocrinopathy,
enteropathy X-linked)
IPEX syndrome is a recessive X-linked disorder, characterized
by immune dysregulation, polyendocrinopathy, dermatitis and
enteropathy since the first months of life. It is caused by mutations
of FOXP3 gene that has a key role in the development of regulatory
T cells. Patients can be more susceptible to infections (sepsis,
meningitis, osteomyelitis, pneumonia) caused by Staphylococcus,
Candida and CMV, probably due to modifications in cutaneous
and gastrointestinal barriers. In IPEX patients killed, inactivated
and recombinant vaccines can be administered [75]. However,
additional studies on the immune response to these vaccines are
required. No data are available on live attenuated vaccines, sug-
gesting that each patient will require a complete immunologic
evaluation before administering these types of vaccines.
5.6. APECED syndrome (autoimmune polyendocrinopathy-candidiasis-
ectoderma dystrophy)
APECED syndrome is also known as autoimmune polyglandular
syndrome type 1 (APS1). It is due to the mutation of AIRE (auto-
immune regulator) gene, which is located on chromosome 21
and is inherited as an autosomal recessive trait. The gene product
regulates nuclear transcription responsible for immune self-
tolerance. When the gene is mutated, thymic suppression of lym-
phocyte clones specific for self molecules does not occur, causing
high risk of autoimmunity. Patients are prone to viral and bacterial
infections. Most patients have normal levels of immunoglobulins
and a good response to vaccines. All killed, inactivated and recom-
binant vaccines are safe [66]. Live attenuated vaccines are at pre-
sent contraindicated for the lack of studies.6. Vaccination in secondary immune deficiencies (Table 3)
Secondary immune deficiencies are a wide and heterogeneous
group of disease affecting immune system as a consequence of var-
ious conditions: infectious diseases (mainly HIV infection), hema-
tological malignancies and cancers, metabolic disorders,
treatment with immunosuppressive, anti-inflammatory or biolog-
ical drugs. The impairment in immune response may be at various
stages with different degree of severity. It involves multiple mech-
anisms of the innate and adaptive immunity, thus accounting for
the susceptibility to different types of pathogens depending on
the underlying immune defect and on the time and the extent of
immunosuppressive therapy. Criteria have been defined to distin-
guish high- or low-level immune impairment in the different dis-
ease entities among SID patients. (The Advisory Committee on
Immunization Practices, (ACIP) or IDSA). Numerous small and
medium-sized studies, as well as meta-analysis clearly show that
vaccination with influenza and inactivated vaccines can be safe
and effective and can reduce the healthcare related costs. However,
randomized controlled studies of large populations are not avail-
able in most instances. Most authors recommend vaccination after
evaluating risk/benefit ratio on the basis of the patient’s clinical
history and laboratory tests.
Table 3
Vaccination in secondary immunodeficiency disorders.
TDP IPV Hib HBV HPV Influenza Pneumococcus Meningococcus MMR
Varicella
Rotavirus BCG
S. typhi
Pediatric haematology and oncology
patients during chemotherapy
‘‘Yes ‘‘Yes ‘‘Yes ‘‘Yes No
data
‘‘Yes ‘‘Yes ‘‘Yes No No No
Pediatric haematology and oncology
patients after chemotherapy
1Yes 1Yes 1Yes 1Yes 1Yes 1Yes 1Yes 1Yes Yes^ No data
available
No data
available
HSCT recipients (autologous or allogenic) 2Yes 2Yes 2Yes 2Yes 2Yes 2Yes 2Yes 2Yes Yes§ No No
Anatomical/Functional Asplenia Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No data
available
Biological drugs Yes Yes Yes Yes Yes Yes Yes Yes 3Yes No data
available
No data
available
HIV Yes Yes Yes Yes Yes Yes Yes Yes 4No 4No No
‘‘ Do not administer in the case of lymphocytes count < 1.0  109/L.
1 Administer a booster dose 6 months after the end of chemotherapy.
^ Administer varicella vaccine only in patients in remission for at least 1 year.
2 Administer 6 months after stopping any immunosuppressive therapy.
§ Do not administer within 24 months after SCT, up to 3 months after immunosuppressive therapy or in the case of GVHD.
3 Consider al least one month after stopping of therapy according to patient immune system function.
4 Consider in HIV asymptomatic patients with CD4+ T >200 cells/ll, if older than 5 years, or 15% of lymphocytes if children below the age of 5 years.
Footnotes: Pneumococcal Vaccines
PCV13 (1 dose) followed by PPV23 (1 dose at least 8 weeks after PCV13 and a booster 3–5 years later) in the case of anatomical/functional asplenia and congenital/acquired
immunodeficiency
PCV13 (1 dose) followed by PPV23 (1 dose at least 8 weeks after PCV13) in the case of complement deficiency, TLR 4 and properidin deficiency, hematopoietic stem cell
transplant, immunosuppression due to organ transplant, chemotherapy, high dose steroids, leukaemia, lymphoma, multiple myeloma and diffuse neoplasia.
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One of the major side effects related to the use of chemotherapy
is the patient’s immunosuppression that lasts for the entire period
of treatment up to 6–12 months after suspension. This results in
the disappearance of vaccination immunity in patients who had
completed the vaccination schedule before starting chemotherapy
[76,77]. The incidence of the lack of protective antibody titers,
measured 6–12 months after chemotherapy, varies depending on
the type of vaccine: it is greater for HBV (approximately 50% of
patients), whereas it is lower for measles, mumps, rubella
(between 20% and 40%) and diphtheria-tetanus-polio (between
10% and 30%) [78–80]. In addition, levels of immunoglobulins nor-
malize within weeks after the end of chemotherapy whilst the
functional response of T cells against antigens such as Cytomegalo-
virus, Herpes Simplex Virus 1, Varicella-Zoster, Candida, Tetanus
and Diphtheria recovers in a year or more after treatment [80].
The correlation between the disappearance of vaccination immu-
nity and the type of cancer (acute lymphoblastic leukemia vs acute
myelogenous leukemia vs solid tumors) is not clear. A recent study
has shown that the recovery of new transitional B cell and naïve B
and T lymphocyte occurs rapidly, while the recovery of memory B
and T cells is slower and may be incomplete up to 5 years after the
end of treatment especially in the case of high intensity regimens
of chemotherapy. It is obvious that appropriate vaccination strate-
gies can reduce complications arising from vaccine preventable
infections, however, some precautions should be taken in relation
to the state of immunological impairment of oncology patients. In
particular, the risk–benefit ratio should be considered for each vac-
cine as well as the correct timing, in order to both avoid any vac-
cine diseases and to allow the patient’s immune system to
mount an adequate antibody response.
 Vaccination during chemotherapy
The major drawbacks of administering vaccinations during
chemotherapy are the potentially suboptimal antibody response,
resulting in reduced protective effectiveness on one side and the
risk associated with live vaccines on the other. However, in this
period patients show an increased susceptibility to vaccine-
preventable infections.Regarding the indication to vaccinations, the quality of evidence
in support of the recommendations is fairly low because of the lack
of methodologically strong studies.
In general, during chemotherapy, vaccines containing inacti-
vated organisms or purified antigens are not contraindicated
[81–88]. In contrast, vaccination with live attenuated viruses are
contraindicated to avoid risks of vaccination disease and/or for lack
of data of effectiveness [89,90]. Vaccination is recommended when
there is both a favorable cost/benefit ratio of the desired protective
effect and the patient’s immune system has the ability to mount an
adequate vaccine response. Currently this ratio is known to be pos-
itive for vaccinations against hepatitis B and against influenza with
inactivated virus. Conjugate pneumococcal vaccine should be
administered at diagnosis and inactivated influenza vaccine should
be administered annually [6]. In any case, the immunization of
patients, when considered useful, should only be done during the
low intensity phase of chemotherapy regimen, as indicated by a
lymphocyte count > 1000/mm3, that allows the patient to mount
an adequate immune response and/or reduce the risk of side
effects. Administration of live attenuated virus vaccines is
contraindicated.
 Vaccination after chemotherapy
Regarding the indication to vaccinations after stopping
chemotherapy, the quality of evidence is better. The previously
acquired immunity does not appear to be completely lost
[80,91,92] and most authors agree that the interval of 6–12
months is adequate to achieve a sufficient immune recovery,
allowing patients to be protected and to contribute to herd
immunity. Revaccination or administration of a booster dose
either 6 months after the end of chemotherapy for vaccines
based on proteins, extracted cellular components or obtained
by recombinant DNA or after 6–12 months for live attenuated
vaccines based on viruses has been proved effective in bringing
protective antibody high titer values in almost all patients, with
no significant side effects [89,93–95]. With regards to varicella
zoster virus, vaccination may be considered in patients in remis-
sion for at least 12 months [90] As for capsulated bacteria
(meningococcus, haemophilus influenza and pneumococcus),
vaccination is indicated in patients with surgical or post-
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in order to prevent meningitis and sepsis [87,93,96]. Differently
from other vaccinations, inactivated influenza vaccine is already
recommended from 3 months after the end of chemotherapy
[97]. There is no need to assess antibody titers either before or
after the revaccination program.6.2. Vaccination and stem cell transplant
The loss of vaccine immunity that occurs after SCT depends on:
– Strength of pretransplant immunity of the patient and the
donor’s immune status;
– Age of the patient at the time of transplantation,
– Combination of pretransplant chemotherapy regimens and/or
radiation therapy;
– Occurrence of GVHD;
– Immunosuppressive therapy following transplantation.
The risk of losing the vaccine immunity is similar after allo-
geneic and autologous SCT.
Up to now, there are only limited data regarding the effec-
tiveness of vaccines in patients undergoing allogeneic
haematopoietic stem cell transplantation. The antibody titer
against the vaccine antigens, (eg. tetanus, polio, measles, mumps,
rubella) is reduced after HSCT in a period of time comprised
between 1 and 10 years. The immune response to the vaccine
is usually low in the first 6 months after SCT. The count of B-
cells, takes 3–12 months to return to normal values. Further-
more, newly generated B cells often show defective Ag-specific
response during the first year after transplantation, due to a lim-
ited capacity of naïve B cells to undergo isotype switching and
somatic mutations [98]. The majority of circulating T cells in
the first year after transplantation are T memory/effector,
derived from the graft and able to respond to antigens encoun-
tered by the donor before transplantation. The naive T cells cap-
able of responding to new antigens are generated only 6–12
months after transplant and this occurs earlier in young children
than in older ones. A better response to vaccination has been
demonstrated in the cases in which donors themselves have
been immunized against hepatitis B, tetanus, Hib and with pneu-
mococcal conjugate vaccines [99]. Vaccines containing inacti-
vated organisms or purified antigens, have a good safety
profile and are not associated with an increased risk of side
effects compared to healthy patients. They should be considered
in every single case and should be given 6 months after stopping
any immunosuppressive therapy. Three doses of DTP-Polio-Hib-
HBsAg, separately or in combination according to age (hexava-
lent can be used up to the 7th year), 2 doses of conjugate pneu-
mococcal vaccine, 2 doses of MenB and 2 doses of conjugate
Men A,C,W,Y vaccine should be given. Inactivated influenza vac-
cine should be given annually [6]. Vaccines containing live
organisms may cause significant disease in immunocompromised
patients and should not be used within 24 months from SCT or
in patients with GVHD or immunosuppressive therapy ongoing
[100].
Two doses of MPR and varicella vaccines should be given 24
months after HSCT, provided that the last Ig infusion was given
at least 11 months before, no GVHD is present and immunosup-
pressive therapy has been stopped at least 3 months before [101].
Inactivated influenza vaccine is recommended for all SCT
patients at least 4–6 months after SCT [6,11,101]. Stem cell or
BM donor who has not received recommended vaccinations should
be vaccinated for his/her own health; vaccination of donor aimed
to the recipent’s benefit is nor recommended. Vaccination of donorwith live vaccines (MPR, varicella, zoster) should be avoided within
4 weeks of donation [6].6.3. Solid organ transplant
Individuals with chronic or end-stage organ diseases and solid
organ transplantation candidates, should receive all vaccinations
as appropriate for age, and immune status based on the annual
immunization schedule for immunocompetent people before
entering the waiting list for transplantation. Transplanted patients
should receive 2 doses of PCV13 2–6 months after transplantation
if not administered before. Inactivated vaccines should be given 2–
6 months after the organ transplant, according to the vaccination
schedule considering the state of immunosuppression. Live vacci-
nes should be avoided; there are no data on safety and effective-
ness except for varicella in non-immune children undergoing
liver or kidney transplant and no signs of immunosuppression
and rejection [6].6.4. Vaccination and asplenia
Individuals with anatomic or functional asplenia (sickle cell
anemia, irradiated subjects, thalassemia, Gaucher, etc.) have an
increased risk of fulminant bacteremia associated with a high mor-
tality rate. Streptococcus pneumoniae is the most common pathogen
causing septicemia in children with asplenia, followed by Hae-
mophilus influenzae type b, Neisseria meningitidis, Escherichia coli,
Staphylococcus aureus, and gram-negative bacilli such as Salmonella
species, Klebsiella species and Pseudomonas aeruginosa. These
patients are at increased risk of fatal malaria and severe babesiosis.
The risk of invasive bacterial infection is higher in the first years
after surgical splenectomy and in younger children than in older
ones. All vaccines are safe and probably effective and none is con-
traindicated except live attenuated influenza vaccine in patients
with sickle cell disease [6]. Pneumococcal conjugate and polysac-
charide vaccines (Hib vaccine and meningococcal conjugate) are
essential for all children with asplenia and must follow the sched-
ule of healthy subjects. In general, when planning an elective
splenectomy all these vaccines should be administered (if not
already practiced) at least 2 weeks prior to surgery [27]. PPSV23
should be administered to asplenic patients aged 2 years at least
8 weeks after PCV13 and a second dose of PPSV23 should be
administered 5 years later. Quadrivalent meningococcal vaccine
MCV4 should be administered to patients aged 2 months with a
revaccination every 5 years[6].6.5. Vaccination and steroid therapy
Children receiving either a dose of prednisone (or equivalent of
other steroids) equal to or more than 2 mg/kg/day or a total dose of
20 mg/day if they weigh mote than 10 kg, must not be vaccinated
with live viruses before 2 weeks if they have undergone therapy for
less than 14 days, or 4 weeks if they have undergone therapy for
more than 14 days.
In individuals using:
 steroids at low or moderate doses (<2 mg/kg) for less than 2
weeks
 steroids physiological maintenance doses (replacement
therapy)
 topical, intra-articular, conjunctival steroids or steroid aerosol
(unless it is suspected systemic immunosuppression), all the
necessary vaccinations can be carried out during treatment,
including those with live attenuated viruses[27].
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HIV disease is currently the most frequent secondary immun-
odeficiency and is characterized by profound T-cell lymphopenia,
which is due to several mechanisms: HIV-induced apoptosis,
viral cytopathic effect, and apoptosis secondary to immune acti-
vation. The immunological profile of HIV infection is peculiar. In
fact, patients show a condition of hypergammaglobulinemia and
a T cell defect that negatively affects the development of specific
antibody responses to various T cell dependent antigens, in par-
ticular encapsulated bacteria [102]. In HIV patients, especially
those with CD4+ T-cell count lower than 200 cells/mmc, oppor-
tunistic infections as Pneumocystis jiroveci pneumonia, histoplas-
mosis, toxoplasmosis and coccidioidomycosis are common.
Recommendations differ according to the severity of the clinical
condition of each patient. In particular, live vaccines should be
considered in HIV asymptomatic patients with CD4+ T >200
cells/ll, if older than 5 years, or 15% of lymphocytes if children
below the age of 5 years.
Conversely, live vaccine are contraindicated in HIV patients
showing high immune suppression, namely: CD4+ T <200 cells/
ll, if older than 5 years, or <15% of lymphocytes, if children below
the age of 5 years. All inactivated vaccines should be given accord-
ing to schedule for immunocompetent people, vaccines against
Haemophilus influenzae, PCV, PPSV23 inactivated influenza, HBV
and Neisseria meningitidis are recommended [27].6.7. Lymphoproliferative diseases
Lymphoproliferative diseases, such as Chronic Lymphocytic
Leukemia (CLL) and Multiple Mieloma (MM), mainly affect adult
people and are associated with higher risk to develop infections,
observed in roughly 50% of these patients, with a mortality rate
accounting for up to 20–25% [103]. Susceptibility to infections is
multifactorial and may be related to both intrinsic immunological
impairment (hypogammaglobulinemia, T- and NK-cells defect,
innate immunity dysfunctions) and chemo-immunotherapy treat-
ment regimens. Hypogammaglobulinemia, whose prevalence
ranges from 20 to 70%, is the most common immune defect in
patients with CLL and worsens even in the absence of disease pro-
gression [104]. Similar to B-cell defects, T-cell defects are related to
the stage of disease and become more pronounced in advanced
stage [105]. Most of the infections are caused by Staphylococcus
aureus, Streptococcus pneumoniae, Haemophilus influenzae,
Escherichia coli, Klebsiella pneumoniae and Pseudomonas aerugi-
nosa and involve the respiratory tract (bronchitis and pneumonia),
the skin, the genito-urinary and the gastrointestinal tract. The use
of purine analogues and monoclonal antibodies, such as rituximab
and alemtuzumab, has changed the spectrum of involved patho-
gens so that infections by protozoa, fungi and viruses have become
frequent. To date, two main strategies are used in patients with
hypogammaglobulinemia who develop recurrent bacterial infec-
tions: antibiotic prophylaxis and IgG replacement therapy
[104,106,107]. Vaccine guidelines for patients affected by lympho-
proliferative disease are not available [108]. Different schedules of
vaccination have been suggested in studies carried out on small
cohorts of patients. The immunological response is more adequate
if patients receive protein, conjugate and adjuvant vaccines. How-
ever, it is not clear whether vaccination response differs in patients
with active disease in comparison to patients in remission
[109,110]. Vaccines containing purified antigens or inactivated
organisms, including pneumococcal or seasonal influenza vaccine,
have a good safety profile and are not associated with increased
risk of side effects compared to healthy patients. Thus, they should
be recommended. Live vaccines are generally contraindicated andmay be considered only during remission, after stopping
chemotherapy and if the level of immunosuppression is low.
6.8. Biological drugs
Biologic response modifiers, such as etanercept, infliximab, ana-
kinra, tocilizumab, are antibodies against proinflammatory cytoki-
nes or proteins that target cytokine receptors on lymphocytes.
These drugs are used to treat several immune-mediated or autoin-
flammatory diseases and are often used in combination with other
immunosuppressive drugs, such as methotrexate or corticos-
teroids. Biologic responsemodifiers are considered highly immuno-
suppressivetheir immune-modulating effects can last for weeks to
months after discontinuation. Other biological drugs such as
monoclonal antibodies anti CD-20 (rituximab) and anti CD-52
(alemtuzumab) were firstly introduced for the treatment of hema-
tological malignancies. They were later used to treat refractory
autoimmune and inflammatory disorders as well. However, they
are also thought to induce secondary immune deficiencies.
Removal of CD20+ cells induces an impairment of B cells regulatory
function, which results in a severe iatrogenic hypogammaglobu-
linemia. The acquired hypogammaglobulinemia occurs early after
the start of the therapy and affects 15–40% of patients; it is usually
transient but in some cases can be prolonged over time. Alem-
tuzumab induces neutropenia and T, B and NK-cells reduction at
the start of the treatment. Such changes can last up to one year after
discontinuation of the therapy. Patients treated with biological
drugs are at increased risk of infections; they become highly sus-
ceptible to specific types of pathogens in relation to the mechanism
of action of the drug: viral, bacterial, and/or opportunistic infections
may be very common. Vaccination status should be assessed pre-
treatment and recommended vaccines should be administered.
Recommended vaccines include inactivated influenza vaccine
and either PPSV23 for patients aged 2 years or older, after complet-
ing PCV13 doses on the routine schedule, or PCV13 for patients
aged 6 years or older who had never received PCV13. Inactivated
vaccines are recommended during therapy according to the annual
immunization schedule. Live virus vaccines are contraindicated
during the therapy and for weeks to months after discontinuation
[6,27]. Varicella vaccine is strongly recommended for patients in
whom alemtuzumab might be planned but it can be given only
before starting the therapy.
7. Vaccines for international travel
7.1. Rabies vaccine
Rabies vaccine is an inactivated vaccine, safe in immunocom-
promised patients for preexposure prophylaxis in high-risk occu-
pations and postexposure to an infected animal, together with
rabies immune globulin or when travelling to endemic area [11].
It is appropriate for use also in HCT recipients. Preexposure rabies
vaccination should probably be delayed until 12–24 months after
HCT, whereas postexposure administration of rabies vaccine with
human rabies Ig can be done any time after HCT [101].
7.2. Yellow fever vaccine
There are limited data regarding safety and efficacy of this live
attenuated vaccine. It should not be administered to patients with
severe humoral, cellular and phagocytic immune defect. Also sub-
jects undergoing to immunosuppressive therapy should not
receive this vaccine [27]. When the risk–benefit balance may favor
use of the vaccine, it can be considered in patients with minor anti-
body deficiencies or minimally immunocompromised HIV-infected
individuals [6].
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Although there are no data regarding the safety or immuno-
genicity of inactivated Japanese encephalitis vaccine in immuno-
compromised subjects, it is expected to be generally used as with
most inactivated vaccines [19].
8. Vaccinations for household members and caregivers of the
immunocompromised host
We recommend that all close contacts of a patient with immun-
odepression are immunized against all vaccine preventable dis-
eases, whenever this is possible. In fact, when the patient is
forbidden to receive any vaccine, the only way to protect him is
through protection of the related people. It is then mandatory to
verify that all the contacts are vaccinated: if not already protected,
they can receive all killed, inactivated and recombinant vaccines. In
particular, in older household members, it is suggested to adminis-
ter a booster of anti-pertussis vaccine, since protection obtained
through a previous infection is likely to decrease over time. The
booster should be repeated every ten years [19]. In the case of bac-
terial infection, such as pertussis or meningitis, the patient has
probably been vaccinated, although with less efficacy, or may be
protected by replacement therapy. However, isolating the patient,
observing all the hygienic measures and, in case of meningitis due
to Neisseria meningitidis or Haemophilus influenzae, administering
antibiotic prophylaxis to the subject are advised.
Regarding live attenuated vaccines, it is important to have some
cautions depending on the specific immune defect: if the immuno-
suppression is high, the risk of transmission of vaccine virus and of
development of the disease is real. As reported by the ACIP, live
attenuated influenza vaccine should not be administered in people
who care for PID patients. Otherwise, the contact with immunosup-
pressed patients within 7 days after vaccination should be avoided
due to the risk of virus transmission [111]. Inactivated influenzavac-
cine is recommended in household contacts and a booster is
required when a long time has passed since last dose [21]. Further-
more, in household contacts, live attenuated polio vaccine is con-
traindicated, although this vaccine is no longer used in Europe.
Measles, mumps, rubella, chickenpox and rotavirus can be adminis-
tered to familymembers or other close contacts susceptible to infec-
tion, since the risk of developing the disease is extremely rare [21].
Particularly, adults with primary immune deficiency should avoid
changing the diaper to children vaccinated with rotavirus in the 4
weeks following the immunization [6]. It is also recommended to
verify the immune status against varicella in adult contacts, since
they could be not vaccinated and not protected by natural immu-
nization. If a household member had a rash after varicella vaccine,
the risk of transmission of infection to an immunosuppressed
patient would be very low. The only risky case would be if blisters
appeared in correspondence of the inoculation site: in that case it
would be better to isolate the patient and to treat himwith prophy-
lactic specific immunoglobulins (a single dose within 96 h after
exposure) and to treat the contact with antiviral therapy. In the rare
case of measles in a householdmember, patient must receive speci-
fic immunoglobulins within 6 days from exposure [6].
In summary:
 There are no contraindications for family members to make or
continue the vaccinations recommended by the health care sys-
tem. There is no evidence of human-to-human transmission of
the live attenuated virus vaccine strain MMR
 Vaccination against influenza (inactivated vaccine) is recom-
mended for the entire duration of the patient care. Live attenu-
ated influenza vaccine should not be administered Vaccination against varicella zoster virus is recommended for rel-
atives with no personal history
 Vaccination with live polio is contraindicated: only inactivated
vaccine IPV should be administered [76,101].
9. Conclusions
Whether or not to vaccine immunocompromised patients is a
still open question. In the case of many of these disorders, there
is a lack of information concerning the immunogenicity and safety
of vaccines, mainly because of the variability of the immune
defects among subjects with the same disease. The present uncer-
tainty of which vaccines can be given to immunodeficient patients,
the fear of adverse events following immunization and the growing
social distrust on vaccination, has inevitably lead to a reduced use
of vaccines, even in subjects who could safely receive them. Collab-
orative efforts are needed among healthcare professionels to
increase vaccine coverage. Specialists who care for immunocom-
promised patients share responsibility with the primary care pro-
vider for recommending appropriate vaccinations to these
patients and their household members. Significant campaigns of
education should be provided by specialty centers to the several
subspecialists and primary care providers to favour physician’s
adherence to vaccine recommendations. The vaccination schedule
in people with immune deficiency should always contemplate a
precise assessment of risk-benefits and specific immunization pro-
gram should be performed according to the clinical and immuno-
logical status for each of these conditions. This document
recommends a balance between the need to protect immunocom-
promised subjects and to avoid the potential adverse effects of the
vaccine itself, in order to improve the health and care of these
patients. Further studies of vaccine efficacy and safety in specific
types of immunodeficiency will be needed to support decisions
on indications for vaccination in immunodeficient people.
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